Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.06 | 0.20 | -0.00 |
| FCF Yield | -74.98% | -10.25% | -10.74% | -2.83% |
| EV / EBITDA | -0.86 | -3.14 | -0.95 | -5.22 |
| Quality | ||||
| ROIC | -43.05% | -56.08% | -90.44% | -94.29% |
| Gross Margin | 83.02% | 78.52% | 57.25% | 58.68% |
| Cash Conversion Ratio | 0.58 | 0.33 | 0.12 | 0.14 |
| Growth | ||||
| Revenue 3-Year CAGR | -21.96% | -7.12% | 84.02% | 79.59% |
| Free Cash Flow Growth | -13.63% | -10.45% | 1.89% | -60.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.19 | 0.86 | 0.42 | 0.85 |
| Interest Coverage | -5,954.86 | -9,294.69 | -20,839.17 | -770.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1,174.02 | 46.80 | 38.58 |
| Cash Conversion Cycle | -98.08 | -16.63 | 52.13 | 160.75 |